Vascular involvement in the pathogenesis of idiopathic inflammatory myopathies

References

• Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16(2)193–208
   PubMed Web of Science ®Google Scholar
• Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16(2)209–215
   PubMed Web of Science ®Google Scholar
• Goncalves FG, Chimelli L, Sallum AM, Marie SK, Kiss MH, Ferriani VP. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J Rheumatol 2002; 29(6)1301–1307
   PubMed Web of Science ®Google Scholar
• Sewry CA, Dubowitz V, Abraha A, Luzio JP, Campbell AK. Immunocytochemical localisation of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage. J Neurol Sci 1987; 81(2–3)141–153
   PubMed Web of Science ®Google Scholar
• Komiya T, Negoro N, Kondo K, Miura K, Hirota Y, Yoshikawa J. Clinical significance of von Willebrand factor in patients with adult dermatomyositis. Clin Rheumatol 2005; 24(4)352–357
   PubMed Web of Science ®Google Scholar
• Guzman J, Petty RE, Malleson PN. Monitoring disease activity in juvenile dermatomyositis: The role of von Willebrand factor and muscle enzymes. J Rheumatol 1994; 21(4)739–743
   PubMed Web of Science ®Google Scholar
• Ganczarczyk ML, Lee P, Armstrong SK. Nailfold capillary microscopy in polymyositis and dermatomyositis. Arthritis Rheum 1988; 31(1)116–119
   PubMedGoogle Scholar
• Wargula JC, Lovell DJ, Passo MH, Bove KE, Santangelo JD, Levinson JE. What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis?. Clin Exp Rheumatol 2006; 24(3)333–343
   PubMed Web of Science ®Google Scholar
• Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, Tonali P. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994; 95(1)166–172
   PubMed Web of Science ®Google Scholar
• Cid MC, Grau JM, Casademont J, Tobias E, Picazo A, Coll-Vinent B, Esparza J, Pedrol E, Urbano-Marquez A. Leucocyte/endothelial cell adhesion receptors in muscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 1996; 104(3)467–473
   PubMed Web of Science ®Google Scholar
• De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994; 53(4)369–376
   PubMed Web of Science ®Google Scholar
• Tews DS, Goebel HH. Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995; 59(1–2)185–194
   PubMed Web of Science ®Google Scholar
• Sallum AM, Kiss MH, Silva CA, Wakamatsu A, Vianna MA, Sachetti S, Marie SK. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 2006; 5(2)93–100
   PubMed Web of Science ®Google Scholar
• Sallum AM, Marie SK, Wakamatsu A, Sachetti S, Vianna MA, Silva CA, Kiss MH. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 2004; 31(4)801–807
   PubMed Web of Science ®Google Scholar
• Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: Important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002; 46(4)1044–1055
   PubMedGoogle Scholar
• Kumamoto T, Abe T, Ueyama H, Sugihara R, Shigenaga T, Tsuda T. Elevated soluble intercellular adhesion molecules-1 in inflammatory myopathy. Acta Neurol Scand 1997; 95(1)34–37
   PubMed Web of Science ®Google Scholar
• Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147(11)3788–3793
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994; 76(2)301–314
   PubMed Web of Science ®Google Scholar
• Rice GE, Munro JM, Corless C, Bevilacqua MP. Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 1991; 138(2)385–393
   PubMed Web of Science ®Google Scholar
• Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol 1995; 155(8)3856–3865
   PubMed Web of Science ®Google Scholar
• Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990; 144(12)4579–4586
   PubMed Web of Science ®Google Scholar
• Lindvall B, Dahlbom K, Henriksson KG, Srinivas U, Ernerudh J. The expression of adhesion molecules in muscle biopsies: The LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand 2003; 107(2)134–141
   PubMed Web of Science ®Google Scholar
• van Dinther-Janssen AC, Horst E, Koopman G, Newmann W, Scheper RJ, Meijer CJ, Pals ST. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol 1991; 147(12)4207–4210
   PubMed Web of Science ®Google Scholar
• Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000; 43(2)336–348
   PubMedGoogle Scholar
• Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: A quantitative study. Ann Neurol 1990; 27(4)343–356
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325(21)1487–1498
   PubMed Web of Science ®Google Scholar
• Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314(6)329–334
   PubMed Web of Science ®Google Scholar
• Isenberg DA. Immunoglobulin deposition in skeletal muscle in primary muscle diseases. Q J Med 1983; 52(207)297–310
   PubMedGoogle Scholar
• Cervera R, Ramirez G, Fernandez-Sola J, D'Cruz D, Casademont J, Grau JM, et al. Antibodies to endothelial cells in dermatomyositis: Association with interstitial lung disease. BMJ 1991; 302(6781)880–881
   PubMedGoogle Scholar
• Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84(6)1974–1981
   PubMed Web of Science ®Google Scholar
• Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med 1991; 91(2)162–168
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum 2002; 46(2)467–474
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329(27)1993–2000
   PubMed Web of Science ®Google Scholar
• Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94(5)1729–1735
   PubMed Web of Science ®Google Scholar
• Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjornsson M, Lindvall B, Lundberg IE. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007; 66(10)1276–1283
   PubMed Web of Science ®Google Scholar
• El Awad B, Kreft B, Wolber EM, Hellwig-Burgel T, Metzen E, Fandrey J, Jelkmann W. Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 2000; 58(1)43–50
   PubMed Web of Science ®Google Scholar
• Falanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB. Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J Invest Dermatol 1991; 97(4)634–637
   PubMed Web of Science ®Google Scholar
• Salven P, Hattori K, Heissig B, Rafii S. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002; 16(11)1471–1473
   PubMedGoogle Scholar
• Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W, Burns DK, Goldstein A, Stern D. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992; 90(6)2333–2339
   PubMed Web of Science ®Google Scholar
• Chung YL, Wassif WS, Bell JD, Hurley M, Scott DL. Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2003; 42(2)298–303
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Park JH. MRS and NIRS for muscle disease evaluation. Bull Rheum Dis 1995; 44(5)4–7
   PubMedGoogle Scholar
• Park JH, Kari S, King LE, Jr, Olsen NJ. Analysis of 31P MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: Dermatomyositis. NMR Biomed 1998; 11(4–5)245–256
   PubMed Web of Science ®Google Scholar
• Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL, Price RR, Olsen NJ. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994; 37(5)736–746
   PubMedGoogle Scholar
• Ogawa S, Shreeniwas R, Butura C, Brett J, Stern DM. Modulation of endothelial function by hypoxia: Perturbation of barrier and anticoagulant function, and induction of a novel factor X activator. Adv Exp Med Biol 1990; 281: 303–312
   PubMedGoogle Scholar
• Carry MR, Ringel SP, Starcevich JM. Distribution of capillaries in normal and diseased human skeletal muscle. Muscle Nerve 1986; 9(5)445–454
   PubMed Web of Science ®Google Scholar
• Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: A distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28(1)8–17
   PubMed Web of Science ®Google Scholar
• De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989; 94(1–3)181–192
   PubMed Web of Science ®Google Scholar
• Girard JP, Springer TA. High endothelial venules (HEVs): Specialized endothelium for lymphocyte migration. Immunol Today 1995; 16(9)449–457
   PubMedGoogle Scholar
• Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40(5)865–874
   PubMed Web of Science ®Google Scholar
• Jerusalem F, Rakusa M, Engel AG, MacDonald RD. Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies. J Neurol Sci 1974; 23(3)391–402
   PubMed Web of Science ®Google Scholar
• Vlodavsky EA, Ludatscher RM, Sabo E, Kerner H. Evaluation of muscle capillary basement membrane in inflammatory myopathy. A morphometric ultrastructural study. Virchows Arch 1999; 435(1)58–61
   PubMed Web of Science ®Google Scholar
• Norton WL, Hurd ER, Lewis DC, Ziff M. Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: Quantitative study of the microvascular bed. J Lab Clin Med 1968; 71(6)919–933
   PubMed Web of Science ®Google Scholar
• Finol HJ, Montagnani S, Marquez A, Montes de Oca I, Muller B. Ultrastructural pathology of skeletal muscle in systemic lupus erythematosus. J Rheumatol 1990; 17(2)210–219
   PubMed Web of Science ®Google Scholar
• Vianna MA, Borges CT, Borba EF, Caleiro MT, Bonfa E, Marie SK. Myositis in mixed connective tissue disease: A unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arq Neuropsiquiatr 2004; 62(4)923–934
   PubMed Web of Science ®Google Scholar
• Niinikoski J, Paljarvi L, Laato M, Lang H, Panelius M. Muscle hypoxia in myositis. J Neurol Neurosurg Psych 1986; 49(12)1455
   PubMed Web of Science ®Google Scholar
• Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246(4935)1309–1312
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246(4935)1306–1309
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Mackiewicz Z, Povilenaite D, Sukura A, Hukkanen M, Virtanen I. Disease-associated increased HIF-1, alphavbeta3 integrin, and Flt-1 do not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies. Rheumatol Int 2004; 24(6)333–339
   PubMed Web of Science ®Google Scholar
• Grundtman C, Tham E, Ulfgren AK, Lundberg IE. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008; 58(10)3224–3238
   PubMedGoogle Scholar
• Hollemann D, Budka H, Loscher WN, Yanagida G, Fischer MB, Wanschitz JV. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006; 3: 2
   PubMedGoogle Scholar
• Hollemann D, Budka H, Loscher WN, Yanagida G, Fischer MB, Wanschitz JV. Endothelial and myogenic differentiation of hematopoietic progenitor cells in inflammatory myopathies. J Neuropathol Exp Neurol 2008; 67(7)711–719
   PubMed Web of Science ®Google Scholar
• Gollnick PD, Saltin B. Significance of skeletal muscle oxidative enzyme enhancement with endurance training. Clin Physiol 1982; 2(1)1–12
   PubMedGoogle Scholar
• Lundberg IE, Nader GA. Molecular effects of exercise in patients with inflammatory rheumatic disease. Nat Clin Pract Rheumatol 2008; 4(11)597–604
   PubMedGoogle Scholar
• Dastmalchi M, Alexanderson H, Loell I, Stahlberg M, Borg K, Lundberg IE, Esbjornsson M. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 2007; 57(7)1303–1310
   PubMedGoogle Scholar
• Hildebrand IL, Sylven C, Esbjornsson M, Hellstrom K, Jansson E. Does chronic hypoxaemia induce transformations of fibre types?. Acta Physiol Scand 1991; 141(3)435–439
   PubMedGoogle Scholar
• Simoneau JA, Lortie G, Boulay MR, Thibault MC, Theriault G, Bouchard C. Skeletal muscle histochemical and biochemical characteristics in sedentary male and female subjects. Can J Physiol Pharmacol 1985; 63(1)30–35
   PubMed Web of Science ®Google Scholar
• Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98(4)1154–1162
   PubMed Web of Science ®Google Scholar